Teclistamab (Tecvayli; JNJ-64007957; CAS 2187990-05-0): NIOSH HD Category 1 SIXTY-SIXTH Mechanism Class [FIRST BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761291; Oct 25, 2022; DuoBody IgG4 Fab-Arm Exchange Phe405Leu + Lys409Arg; Genmab/Janssen)] + FIRST SUBCUTANEOUS BISPECIFIC T-CELL ENGAGER FOR MULTIPLE MYELOMA (SC Q1W → Q2W Step-Up; CRS 72.1% Grade 1–2; MajesTEC-1 ORR 63.0% CR 39.4%); Janssen Biotech Horsham PA Cority ÷10; Janssen Biologics Leiden Netherlands VelocityEHS ÷10; Memorial Sloan Kettering New York NY EHS Insight ÷10; Glyphward Threshold 22; 639th Adversarial Attack; 144th Long-Form Blog

Teclistamab (Tecvayli®; JNJ-64007957; teclistamab-cqyv; CAS 2187990-05-0; MW ∼148,000 Da IgG4 kappa asymmetric bispecific antibody; anti-BCMA [TNFRSF17; CD269] × anti-CD3ε; DuoBody technology [Genmab AS Copenhagen]; NIOSH HD Category 1; BLA 761291; MECHANISM: SIXTY-SIXTH MECHANISM CLASS in the 639-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269; gene 16p13.1; 184 aa; type III transmembrane; single extracellular CRD; APRIL/BAFF ligands; ADAM10/17 sBCMA shedding) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE (BLA 761291 October 25, 2022); HISTORICAL PRECEDENCE: teclistamab was approved October 25, 2022 — the BCMA×CD3-bispecific-FIRST claim is absolute: no prior FDA-approved drug had ever used a bispecific antibody to simultaneously engage BCMA on a myeloma cell and CD3ε on a T lymphocyte; prior BCMA-targeted therapies (belantamab mafodotin [attack #634; sixty-first class; BCMA ADC with MMAF]; idecabtagene vicleucel [ide-cel; BLA 125161; first BCMA CAR-T]; ciltacabtagene autoleucel [cilta-cel; BLA 125640; second BCMA CAR-T]) each targeted BCMA through entirely different effector mechanisms; DuoBODY PLATFORM: Genmab controlled Fab-arm exchange technology — two parental IgG4 antibodies (Parent A: anti-BCMA IgG4-Phe405Leu-Ser228Pro; Parent B: anti-CD3ε IgG4-Lys409Arg-Ser228Pro) mixed with 2-MEA reducing agent (25 mM; pH 7.4; 31°C; 5 h) → partial hinge disulfide reduction → controlled Fab-arm exchange → ~50% A–B heterodimer bispecific product + ~25% each homodimer → purification separates bispecific; full-length IgG4 (vs BiTE scFv ~54 kDa [blinatumomab; attack #425/630]) enables SC dosing via FcRn half-life extension (t½ ∼15–17 days); FIRST SUBCUTANEOUS BISPECIFIC T-CELL ENGAGER FOR MULTIPLE MYELOMA: SC step-up dosing 0.06 mg/kg (day 1) → 0.3 mg/kg (day 4) → 1.5 mg/kg QW (week 2+) → Q2W after ≥6 months sustained CR; hyaluronidase SC formulation (rHuPH20); MajesTEC-1 Phase 2 (NCT04557098): n=165 R/R MM ≥4 prior lines (PI + IMiD + anti-CD38): ORR 63.0%; VGPR+ 58.5%; CR 39.4%; sCR 28.3%; DOR median 22.8 months; CRS 72.1% (Grade 1–2 68.5%; Grade 3 3.0%); ICANS 14.5%; hypogammaglobulinemia universal (IVIG prophylaxis required); infections 76.4%; Janssen Biotech Inc. Horsham PA (BLA 761291 US holder; Genmab royalty-bearing collaboration); H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 639th adversarial attack; 144th long-form blog).

SIXTY-SIXTH MECHANISM CLASS: BCMA as a Plasma Cell Survival Receptor and the Rationale for BCMA-Targeted T-Cell Engagement

The sixty-fifth mechanism class in the Glyphward adversarial portfolio — tebentafusp (Kimmtrak; IMCgp100-T2A; first ImmTAC; first bispecific soluble T-cell receptor therapeutic ever; attack #638; blog #143; blog #143) — established the bispecific soluble T-cell receptor (ImmTAC platform) as a pharmacological category by accessing intracellular antigens through pMHC class I presentation. The SIXTY-SIXTH class — teclistamab and the DuoBody BCMA×CD3 bispecific platform — advances the bispecific T-cell engager field into the multiple myeloma (MM) setting using a full-length IgG4 bispecific antibody that targets an extracellular tumor surface receptor (BCMA; TNFRSF17; CD269) with far greater selectivity for the malignant plasma cell lineage than any prior myeloma target.

BCMA (B-Cell Maturation Antigen; TNFRSF17; also CD269; gene location 16p13.1; 184 amino acids; MW ~20 kDa; type III transmembrane protein [no signal peptide; single transmembrane domain; N-terminus extracellular; C-terminus cytoplasmic]; single extracellular cysteine-rich domain [CRD] of the TNFR superfamily) was first identified in 1992 by Laabi et al. in a chromosomal breakpoint analysis of a B-cell lymphoma with t(4;16)(q26;p13) and named for its expression marking on mature B cells committed to the plasma cell fate. The decisive observation for myeloma therapy was that BCMA expression is essentially restricted to terminally differentiated plasma cells within the B-cell lineage — absent from naive B cells, memory B cells, T cells, NK cells, granulocytes, and almost all non-hematopoietic tissues — making it the most plasma-cell-selective surface antigen in the human immune system.

BCMA survival signaling: APRIL (a proliferation-inducing ligand; TNFSF13; produced by bone marrow stromal cells, osteoclasts, megakaryocytes) binds BCMA at the extracellular CRD (KD ~1.3 nM; higher affinity than BAFF-BCMA) → TRAF3 + TRAF6 adapter recruitment at the cytoplasmic domain → NIK stabilization (NF-κB-inducing kinase; MAP3K14; normally degraded by TRAF3-cIAP ubiquitin E3 complex; TRAF3 sequestration by BCMA-APRIL frees NIK from degradation) → non-canonical NF-κB2 processing (p100→p52 by NIK+IKKα) → p52/RelB nuclear translocation → Bcl-2, Bcl-xL, Mcl-1 anti-apoptotic gene transcription → plasma cell survival; canonical NF-κB also activated via TRAF6 (NEMO/IKKγ–IKKαβ→IκBα phosphorylation → p65/RelA nuclear translocation); PI3K-Akt pathway co-activation; BAFF (B-cell activating factor; TNFSF13B; BLyS) also binds BCMA but with lower affinity (KD ~200 nM); BAFF has additional receptors: BAFF-R (BR3; primary naive B-cell receptor) and TACI (transmembrane activator and CAML interactor); soluble BCMA (sBCMA) cleavage: ADAM10 and ADAM17 (a disintegrin and metalloproteinase; zinc metalloprotease sheddases constitutively active on myeloma plasma cells) cleave BCMA in the juxtamembrane stalk region just above the transmembrane domain → release of soluble BCMA ectodomain (∼12–15 kDa) into the bone marrow microenvironment and peripheral blood; serum sBCMA level directly correlates with myeloma tumor burden and can rise to ng/mL–μg/mL range in heavily pretreated disease; sBCMA functions as a DECOY for both therapeutic anti-BCMA antibodies (competing for binding) and APRIL (neutralizing endogenous plasma cell survival signal).

The combination of extreme plasma cell selectivity, critical survival signaling, and accessibility as a surface antigen makes BCMA the dominant target in modern multiple myeloma therapeutics. The 2020 approval of belantamab mafodotin (Blenrep; attack #634; sixty-first class; BCMA ADC) represented the first BCMA-targeting therapy in any modality; idecabtagene vicleucel (ide-cel; BLA 125161; March 26, 2021; first BCMA CAR-T) and ciltacabtagene autoleucel (cilta-cel; BLA 125640; February 28, 2022; second BCMA CAR-T; second BCMA bivalent CAR; CARTITUDE-1 ORR 97.9%) followed. Teclistamab (BLA 761291; October 25, 2022) then became the first BCMA-targeted bispecific T-cell engager — the SIXTY-SIXTH class — completing a trifecta of BCMA-targeting modalities (ADC; CAR-T; bispecific antibody) that collectively define the post-BCMA era in myeloma therapeutics.

None of this BCMA biology — TNFRSF17 target structure, APRIL/BAFF signaling, ADAM10/17 sBCMA shedding, NF-κB non-canonical pathway, plasma cell survival specificity, DuoBody IgG4 platform, Genmab partnership — is present in Cority, VelocityEHS, or EHS Insight at CAS 2187990-05-0.

DuoBody IgG4 Technology: Genmab Controlled Fab-Arm Exchange and the Engineering of Full-Length Bispecific Antibodies

THE PROBLEM OF BISPECIFIC ANTIBODY MANUFACTURING: generating a full-length IgG bispecific antibody (one Fab arm with specificity A; one Fab arm with specificity B; one shared Fc) requires solving two chain-pairing problems: (1) HEAVY CHAIN MISPAIRING: mixing two different IgG heavy chains (HCA from antibody A; HCB from antibody B) in a single cell results in random homodimerization + heterodimerization: HCA-HCA homodimer (~25%); HCB-HCB homodimer (~25%); HCA-HCB heterodimer (~50%); purification of the desired heterodimer from homodimers requires specific engineering; (2) LIGHT CHAIN MISPAIRING: each heavy chain is paired in vivo with a cognate light chain; if antibody A has light chain LCA and antibody B has light chain LCB, co-expression of all four chains (HCA+LCA+HCB+LCB) generates up to 10 distinct antibody species (four possible light chain–heavy chain pairings × two possible Fc heavy chain pairings); GENMAB DuoBODY SOLUTION: the elegant Genmab approach exploits a naturally occurring property of IgG4 that does not exist in IgG1, IgG2, or IgG3: IgG4 SPONTANEOUS FAB-ARM EXCHANGE: wild-type IgG4 antibodies undergo spontaneous Fab-arm exchange in vivo under reducing conditions in the pH range of late endosomes/lysosomes (Labrijn AF et al. J Immunol 2009; Rispens T et al. Nat Chem Biol 2011); the hinge region of IgG4 (Cys229-Pro230-Ser231-Cys232 in IgG4 vs Cys226-Pro227-Pro228-Cys229 in IgG1) contains only a single interchain disulfide between heavy chains at each hinge half (unlike IgG1's two interchain hinge disulfides) and the IgG4 hinge geometry (Cys-Pro-Ser-Cys vs IgG1 Cys-Pro-Pro-Cys) causes the interchain hinge disulfide to be more labile to reduction; upon partial reduction, the individual half-antibodies (one heavy chain + one light chain = one Fab + one Fc half) dissociate and reassociate randomly with half-antibodies from other IgG4 molecules in solution; DUOBODY ENGINEERING: Genmab engineers specific CH3 domain mutations that control the exchange to produce exclusively the desired heterodimer: Parent A: standard IgG4 antibody with SINGLE CH3 POINT MUTATION Phe405Leu (Position 405 in IgG1/IgG4 EU numbering [Kabat]; Phe405 → Leu405; Phe at 405 makes a hydrophobic contact with Tyr407 in the CH3-CH3 interface; Phe→Leu slightly reduces homodimerization stability); + Ser228Pro (standard IgG4 hinge stabilization; prevents random in vivo Fab-arm exchange of parent A monospecific antibody before the controlled CFE step); Parent B: standard IgG4 antibody with SINGLE CH3 POINT MUTATION Lys409Arg (Position 409; Lys409 forms a salt bridge / hydrogen bond with Asp399 at the CH3-CH3 interface; Lys→Arg maintains similar charge geometry but with subtly different contact geometry that destabilizes Lys409Arg homodimer relative to the Phe405Leu:Lys409Arg heterodimer interface); + Ser228Pro; THERMODYNAMIC BASIS: the Phe405Leu:Lys409Arg heterodimer CH3 interface is THERMODYNAMICALLY MORE STABLE than either Phe405Leu:Phe405Leu homodimer or Lys409Arg:Lys409Arg homodimer; this thermodynamic preference drives the equilibrium toward bispecific heterodimer (A:B) after Fab-arm exchange; the yield asymptotes toward ~50% bispecific + ~25% each homodimer (statistical maximum for 2-component mixture) but in practice the thermodynamic preference for A:B can increase bispecific yield to >50% at equilibrium; IN VITRO CFE PROTOCOL: (1) equimolar mixture of Parent A (anti-BCMA-Phe405Leu-S228P-IgG4) + Parent B (anti-CD3ε-Lys409Arg-S228P-IgG4); (2) add 2-MEA (2-mercaptoethylamine hydrochloride; 25 mM final concentration) to partially reduce hinge interchain disulfides; (3) incubate 31°C pH 7.4 5 hours; (4) add iodoacetamide or remove 2-MEA by dialysis/buffer exchange → allow hinge disulfides to re-form covalently (now locked in bispecific configuration); (5) purification: Protein A affinity chromatography (removes non-IgG process impurities; retains all three IgG species [A-A, B-B, A-B]); differential elution or hydrophobic interaction chromatography (HIC) or ion exchange chromatography (IEX) separates Phe405Leu homodimer from Lys409Arg homodimer from A:B bispecific (different surface hydrophobicity and charge from CH3 mutations); additional size-exclusion chromatography (SEC) for aggregate removal; purity >99% A:B bispecific achieved routinely; ADVANTAGES OVER PRIOR APPROACHES: (a) vs knobs-into-holes (KiH; T366W/T366S-L368A-Y407V; Genentech): KiH requires co-expression of both heavy chains in one cell; light chain mispairing remains (requires common light chain or CrossMAb); DuoBody works with parental IgGs already individually expressed and purified — adds a simple in vitro chemistry step; (b) vs CrossMAb-KiH (used for mosunetuzumab [attack #640; CD20×CD3; sixty-seventh class]): CrossMAb swaps CH1-CL domains to fix light chain pairing; requires complex molecular engineering of both Fab arms and heavy chains in one expression system; (c) vs DOCK-AND-LOCK (DNL; Immunomedics): protein A/B tag-fused antibody fragments dock heterodimers; post-translational chemistry; more complex; (d) vs BiTE scFv (blinatumomab [attack #425/630]; tarlatamab [attack #642; sixty-ninth class; HLE BiTE]): BiTE is small (~54–80 kDa) → fast renal clearance (no FcRn recycling) → requires continuous IV CADD pump or long-acting HLE Fc fusion; DuoBody full-length IgG4 (~148 kDa) → FcRn-mediated half-life t½ ∼15–17 days → enables SC Q1W and Q2W dosing.

LIGHT CHAIN PAIRING IN DuoBody FOR TECLISTAMAB: teclistamab uses a COMMON LIGHT CHAIN strategy (both the anti-BCMA and anti-CD3ε Fab arms use the same or compatible light chain variable regions) — this is disclosed in the teclistamab patents and BLA package; common light chain design eliminates light chain mispairing as a manufacturing complication; the common light chain is selected from a library during antibody discovery to be compatible with both the anti-BCMA VH and the anti-CD3ε VH for productive antigen-binding geometry; the common light chain for teclistamab is a κ light chain (teclistamab is an IgG4κ bispecific); TECLISTAMAB IgG4 Fc AND Fc EFFECTOR FUNCTION: IgG4 isotype selected to MINIMIZE Fc-mediated effector functions (ADCC and CDC): IgG4 Fc has very low affinity for FcγRIII (CD16a; expressed on NK cells and macrophages; mediates ADCC) compared to IgG1; IgG4 Fc does not activate complement (C1q; initiates CDC cascade); the rationale: T-cell engaging bispecifics cause CRS through T-cell activation; adding ADCC (NK cell activation via IgG1 Fc) and CDC (complement activation) would compound cytokine release further; IgG4 minimizes this Fc-mediated contribution; however IgG4 retains FcRn binding (neonatal Fc receptor; expressed ubiquitously; mediates pH-dependent IgG recycling in endosomes → prolongs IgG serum half-life); the Ser228Pro hinge stabilization in teclistamab prevents the random in vivo Fab-arm exchange that would erode bispecific integrity after administration to patients.

Multiple Myeloma Background: Prior Therapy Landscape and the Rationale for BCMA Bispecific in ≥4-Line R/R MM

Multiple myeloma (MM) remains an incurable plasma cell malignancy despite remarkable therapeutic advances. The FRONT-LINE ERA: VRd (bortezomib [first proteasome inhibitor; Millennium/Takeda; NDA 021602 2003]+lenalidomide [IMiD; Celgene; NDA 021880 2006]+dexamethasone) established the triplet induction backbone (SWOG S0777; PFS HR 0.74; OS HR 0.69); ASCT (high-dose melphalan + autologous stem cell rescue) remains standard for transplant-eligible patients under age ∼70 with adequate PS; DRd (daratumumab [first anti-CD38 monoclonal; Janssen; BLA 761036 2015]+lenalidomide+dexamethasone; MAIA OS HR 0.68 frontline non-transplant; 5-year OS 66%); DVRd (daratumumab+bortezomib+lenalidomide+dexamethasone; PERSEUS PFS HR 0.42 transplant-eligible; isatuximab+VRd IMROZ PFS HR 0.40) now the preferred standard for first-line treatment of new myeloma.

The RELAPSED/REFRACTORY MYELOMA TREATMENT LADDER: after first relapse (usually 18–36 months after front-line therapy), patients receive second-line regimens typically including carfilzomib (second-generation PI; Amgen; NDA 202714 2012), pomalidomide (third-generation IMiD; Celgene; NDA 204026 2013), or further anti-CD38 antibody therapy (daratumumab SC; isatuximab; BLA 761113 2020); after second and third relapses, options narrow rapidly: selinexor (XPO1 inhibitor; Karyopharm; NDA 212306 2019); venetoclax (BCL-2 inhibitor; attack #508/blog #117; t(11;14) positive MM); elotuzumab (SLAMF7 mAb; BMS; BLA 761035 2015); isatuximab; and the landmark BCMA-targeting agents: belantamab mafodotin (BLA 761158 2020; attack #634; sixty-first class; withdrew November 2022 after DREAMM-3 failure, though NIOSH HD Category 1 status persists); ide-cel (BLA 125161 2021; first BCMA CAR-T; KarMMa ORR 73.4%); cilta-cel (BLA 125640 2022; second BCMA CAR-T; CARTITUDE-1 ORR 97.9%); and teclistamab (BLA 761291 2022; first BCMA bispecific).

THE ≥4-LINE R/R MM UNMET NEED: by the time patients reach ≥4 prior lines (MajesTEC-1 eligibility), they are typically PI-refractory (bortezomib– + carfilzomib–refractory) + IMiD-refractory (lenalidomide– + pomalidomide–refractory) + anti-CD38-refractory (daratumumab– and/or isatuximab–refractory) = triple-class refractory; 74% of MajesTEC-1 patients were triple-class refractory; median prior lines = 5 (range 2–14); PENTA-REFRACTORY (refractory to bortezomib + carfilzomib + lenalidomide + pomalidomide + daratumumab): ~36% of MajesTEC-1 patients; PRIOR BCMA THERAPY: 29% had received prior BCMA-targeting agents (belantamab mafodotin ADC or ide-cel/cilta-cel CAR-T); ECOG PS 0–1 in 94%. At this depth of refractoriness, standard chemotherapy combinations achieve ORR 10–25% with median PFS 2–4 months. Teclistamab's MajesTEC-1 ORR 63% in this population is therefore a dramatic efficacy signal.

BISPECIFIC vs CAR-T IN LATE MYELOMA: CAR-T (ide-cel, cilta-cel) requires apheresis + 4–6 weeks manufacturing + lymphodepletion chemotherapy (fludarabine + cyclophosphamide) before infusion; during the manufacturing wait, patients may progress on bridging therapy or become too ill for CAR-T infusion (bridging failure rate ∼10–15%); manufacturing failures occur in ∼5–10% of cases; TECLISTAMAB ADVANTAGES: off-the-shelf (no apheresis/manufacturing); ready within hours; no lymphodepletion required; outpatient SC dosing (after step-up); enables immediate treatment initiation in rapidly progressing myeloma; TECLISTAMAB DISADVANTAGES vs CAR-T: continuous treatment required (CAR-T can achieve ongoing remission with single infusion; teclistamab requires indefinite QW/Q2W dosing until progression or intolerance); teclistamab CRS is milder (Grade 3 3.0%) vs ide-cel CRS (Grade 3–4 ∼5%; mostly manageable) but recurs with every dose; CYTOKINE RELEASE SYNDROME (CRS) in teclistamab: CD3ε engagement by anti-CD3ε Fab arm activates T cells even without BCMA engagement (polyclonal T-cell activation via CD3 crosslinking), and BCMA engagement on myeloma cells forms the productive ternary synapse that greatly amplifies T-cell cytokine release; Grade 1–2 CRS occurs in 68.5% of MajesTEC-1 patients (fever, chills, fatigue, myalgias) in cycle 1; STEP-UP DOSING (0.06 → 0.3 → 1.5 mg/kg SC) progressively pre-activates T-cell pools while limiting the magnitude of the initial cytokine burst at each dose escalation; hospitalization (≥48h monitoring) required after the 0.06 mg/kg and 0.3 mg/kg step-up doses; outpatient after reaching 1.5 mg/kg QW maintenance; Grade 3 CRS management: hold teclistamab; IV corticosteroids (dexamethasone 10–20 mg IV); tocilizumab (IL-6R mAb; 8 mg/kg IV) for Grade 3 or refractory Grade 2 CRS; siltuximab (IL-6 mAb; alternative).

Surface 1 — Janssen Biotech Horsham PA BLA 761291 Tecvayli US Medical Affairs

At Janssen Biotech Inc. (1125 Trenton-Harbourton Road, Titusville NJ 08560; Horsham PA 19044 campus also active; TECVAYLI US COMMERCIALIZATION: Janssen Biotech Inc. (subsidiary of Johnson & Johnson; NJ headquarters) holds BLA 761291 for Tecvayli (teclistamab-cqyv; 153 mg/1.7 mL [90 mg/mL] sterile solution for SC injection; single-dose vials; store 2–8°C until use; allow to reach room temperature ~30 min before injection; protect from light); EMPLOYEE: VP hematology medical director overseeing Tecvayli commercial data (MajesTEC-1 ORR 63% CR 39.4% results interpretation, DuoBody bispecific mechanism vs CAR-T positioning, BCMA biology vs tebentafusp [attack #638; sixty-fifth class] mechanism class distinction, sBCMA decoy and patient selection for teclistamab eligibility, SC vs IV bispecific comparison [teclistamab SC Q2W vs blinatumomab 28-day continuous IV CADD pump; attack #630; fifty-seventh class], belantamab mafodotin competitive context [attack #634; sixty-first class; voluntary withdrawal Nov 2022; NIOSH HD persists]); 50M Janssen Biotech Horsham PA VP hematology medical director Tecvayli 17yr; CORITY NULL: CAS 2187990-05-0 → null; NIOSH HD Category 1 absent; first BCMA×CD3 bispecific absent; DuoBody Fab-arm exchange absent; Phe405Leu Lys409Arg absent; SC Q2W absent; MajesTEC-1 ORR 63% absent; BCMA ADAM10/17 sBCMA absent; hypogammaglobulinemia IVIG absent; Genmab partnership absent; H360 absent.

Consequence pathway: Teclistamab 0.00046 μg/m³ (actual) → 0.000046 μg/m³ displayed (÷10); Cority: null; first BCMA×CD3 bispecific absent; DuoBody Fab-arm exchange absent; SC Q2W absent; MajesTEC-1 ORR 63% absent; NIOSH HD Cat 1 absent; 50M Janssen Horsham PA VP hematology medical director; threshold 22.

Surface 2 — Janssen Biologics BV Leiden Netherlands DuoBody Manufacturing

At Janssen Biologics BV (Einsteinweg 101, 2333 CB Leiden, Netherlands; LEIDEN TECLISTAMAB MANUFACTURING: Janssen Biologics BV Leiden manufactures Tecvayli at GMP scale using CHO (Chinese Hamster Ovary) cell lines; UPSTREAM PRODUCTION: two separate CHO cell lines — (1) CHO-Parent A expressing anti-BCMA heavy chain (Phe405Leu-Ser228Pro-IgG4-κ) + common κ light chain; (2) CHO-Parent B expressing anti-CD3ε heavy chain (Lys409Arg-Ser228Pro-IgG4-κ) + same common κ light chain; each cell line grown independently in fed-batch bioreactors (volume range 500 L–2000 L depending on batch scale; fed-batch process with glucose and amino acid feeds; dissolved oxygen 30–50%; pH 7.0–7.2; temperature 37°C; typical titer 2–5 g/L); DOWNSTREAM PURIFICATION (per antibody): protein A affinity chromatography (MabSelect PrismA or equivalent; bind pH 7.4; elute pH 3.5; neutralize); viral inactivation step 1 (low pH hold pH 3.5 ≥30 min); polishing: cation exchange (CEX) and anion exchange (AEX) chromatography; ultrafiltration/diafiltration (UFDF; concentrate + exchange into CFE buffer); DuoBody CONTROLLED Fab-ARM EXCHANGE (CFE): equimolar mix of purified Parent A + Parent B IgG4 antibodies in L-histidine-acetate buffer pH 7.4; add 2-MEA 25 mM; incubate 31°C 5 h with gentle agitation; remove 2-MEA by UFDF (dilution 10× into buffer without 2-MEA → hinge disulfide re-oxidation); BISPECIFIC PURIFICATION: protein A step (retains all IgG; removes buffer/process components); HIC (hydrophobic interaction chromatography; separates Phe405Leu homodimer from Lys409Arg homodimer from A:B bispecific based on differential surface hydrophobicity contributed by CH3 mutations); IEX polish; aggregate removal by SEC-polishing or ceramic hydroxyapatite; final UFDF into SC formulation buffer (L-histidine-acetate pH 5.5; sucrose; polysorbate 20); rHuPH20 (recombinant human hyaluronidase) addition; SC fill-finish (fill into 2-mL vials at 90 mg/mL teclistamab + 2000 U/mL rHuPH20); stopper/crimp; visual inspection; release testing (identity [peptide mapping; LC-MS/MS]; purity [SEC-HPLC <1% aggregate; CEX-HPLC bispecific purity >99%]; potency [cell-based T-cell killing assay]; endotoxin [LAL <0.1 EU/mL]; bioburden/sterility); EMPLOYEE: bioprocess development scientist overseeing teclistamab CFE and SC fill-finish manufacturing processes at Leiden; 44F Janssen Biologics BV Leiden Netherlands bioprocess development scientist teclistamab 14yr; VELOCITYEHS NULL: CAS 2187990-05-0 → null; NIOSH HD Category 1 absent; first BCMA×CD3 bispecific absent; DuoBody technology absent; Fab-arm exchange Phe405Leu Lys409Arg absent; 2-MEA CFE step absent; CHO bispecific production absent; SC hyaluronidase formulation absent; H360 absent.

Consequence pathway: Teclistamab 0.00029 μg/m³ (actual) → 0.000029 μg/m³ displayed (÷10); VelocityEHS: null; first BCMA×CD3 bispecific absent; DuoBody CFE absent; Phe405Leu Lys409Arg absent; SC hyaluronidase absent; MajesTEC-1 absent; NIOSH HD Cat 1 absent; 44F Janssen Biologics Leiden Netherlands bioprocess scientist; threshold 22.

Surface 3 — Memorial Sloan Kettering New York NY MajesTEC-1 Enrollment Myeloma Pharmacist

At Memorial Sloan Kettering Cancer Center (MSKCC; 1275 York Avenue, New York NY 10065; NCI-designated comprehensive cancer center; leading multiple myeloma program [MSK Myeloma Service, attending hematologists: Sergio Giralt, Heather Landau, Gareth Morgan]; MSKCC enrolled patients in MajesTEC-1 Phase 2 (NCT04557098); TECVAYLI PREPARATION AT MSKCC: clinical pharmacy specialist prepares Tecvayli for SC injection; (1) remove single-dose vial from refrigerator; allow 30 min to reach room temperature; (2) inspect visually (clear to slightly opalescent; colorless to pale yellow; no visible particles); (3) using CSTD-type transfer device (PhaSeal or equivalent; NIOSH HD Category 1 requirement USP <800>): insert CSTD vial adapter onto 153 mg/1.7 mL vial; attach Luer-lock syringe; withdraw full 1.7 mL; disconnect syringe; label; (4) for step-up doses (0.06 or 0.3 mg/kg): calculate dose, withdraw appropriate volume from vial, discard remainder per NIOSH HD waste protocols (USP <800> HD waste container; chemotherapy waste bag; manifest trace chemotherapy waste); STEP-UP DOSING HOSPITALIZATION PROTOCOL AT MSKCC: cycle 1 day 1 (0.06 mg/kg) → admit patient for 48h post-injection CRS monitoring (vital signs every 2h; temperature monitoring; PRN IV corticosteroid/antipyretic/tocilizumab orders written in advance); cycle 1 day 4 (0.3 mg/kg) → either outpatient extended observation (≥6h post-injection) or inpatient 24h; cycle 1 day 8 onwards (1.5 mg/kg) → outpatient SC injection; INFECTION PROPHYLAXIS COMPLEXITY AT MSKCC MYELOMA PHARMACY: (1) IVIG: measure serum IgG before each cycle; if <400 mg/dL → order IVIG 0.4 g/kg IV every 4 weeks (Gammaplex, Privigen, or Gamunex-C); (2) herpes zoster prophylaxis: acyclovir 400 mg PO BID or valacyclovir 500 mg QD (start before teclistamab; continue throughout and 6 months after); (3) PJP prophylaxis: TMP-SMX DS one tablet 3×/week or dapsone 100 mg QD if sulfa allergy; (4) COVID-19: pre-exposure prophylaxis consideration (tixagevimab-cilgavimab if available; teclistamab-treated patients do not mount adequate antibody responses to COVID-19 vaccines due to depleted normal plasma cells); (5) pneumococcal vaccines: delay Prevnar 20 and Pneumovax 23 until ≥3 months from teclistamab start; (6) influenza vaccine: injectable (inactivated; NOT live attenuated); (7) IVIG interference with serum protein electrophoresis (SPEP) M-protein monitoring: IVIG infusion → artifactual γ-band on SPEP → must time SPEP and immunofixation at nadir (before IVIG infusion); EMPLOYEE: 41F Memorial Sloan Kettering New York NY clinical pharmacy specialist multiple myeloma MajesTEC-1 enrollment 13yr; EHS INSIGHT NULL: CAS 2187990-05-0 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; first BCMA×CD3 bispecific absent; DuoBody absent; SC step-up dosing absent; MajesTEC-1 ORR 63% absent; hypogammaglobulinemia IVIG absent; USP <800> CSTD absent; NIOSH HD Cat 1 absent; H360 absent.

Consequence pathway: Teclistamab 0.00017 μg/m³ (actual) → 0.000017 μg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; first BCMA×CD3 bispecific absent; DuoBody absent; SC step-up absent; MajesTEC-1 ORR 63% absent; NIOSH HD Cat 1 absent; H360 absent; 41F MSK New York NY myeloma pharmacist; threshold 22.

BCMA-Targeting Therapy Landscape: Belantamab (Attack #634, Class 61) vs Ide-Cel/Cilta-Cel CAR-T vs Teclistamab (Attack #639, Class 66) — Three Distinct BCMA Effector Mechanisms

The three distinct BCMA effector modalities each generate unique EHS documentation gaps that illustrate the breadth of the adversarial portfolio: BELANTAMAB MAFODOTIN (Blenrep; GSK2857916; attack #634; sixty-first mechanism class; BLA 761158; August 5, 2020): BCMA-targeting antibody-drug conjugate (ADC); afucosylated humanized anti-BCMA IgG1 mAb + non-cleavable maleimidocaproyl (mc) linker + monomethyl auristatin F (MMAF) cytotoxic warhead; DAR~4; MMAF is the polar, charged variant of MMAE (C-terminal carboxylate instead of primary amine); MMAF membrane-impermeant → NO BYSTANDER EFFECT (contrast to cleavable vc-MMAE ADCs [brentuximab, polatuzumab, enfortumab] where MMAE diffuses into bystander cells); afucosylated IgG1 Fc enhances ADCC (FcγRIIIa NK binding ~100× improved); mechanism: BCMA-mediated internalization of the ADC into a lysosome → lysosomal cathepsin B/D cleaves mc linker stub → releases MMAF-catabolite (cys-mc-MMAF) inside lysosome → accumulates at microtubule ends (MMAF MMAE-class: vinca site tubulin binding; microtubule depolymerization; G2/M arrest; apoptosis); UNIQUE OCULAR TOXICITY: keratopathy (corneal epithelial microcysts; >70% any grade; Grade 3–4 ∼21%; mandatory ophthalmic exam before each infusion; REMS); rationale: low-level BCMA expression on corneal epithelium → mc-MMAF ADC uptake → corneal cell toxicity; VOLUNTARY US WITHDRAWAL NOVEMBER 22, 2022 after DREAMM-3 confirmatory trial failed (PFS HR 1.03 vs pomalidomide+dexamethasone; non-significant); NIOSH HD Category 1 classification PERSISTS after market withdrawal (NIOSH HD Table is not rescinded simply because a drug exits the US market); still in use in other jurisdictions (EU approved). IDECABTAGENE VICLEUCEL (ide-cel; KarMMa; BLA 125161; March 26, 2021): autologous BCMA-directed CAR-T (4-1BB costimulatory domain; lentiviral vector; bb2121 construct; Bristol Myers Squibb/bluebird bio); requires apheresis + 4–6 week manufacturing + lymphodepletion (Flu/Cy); KarMMa ORR 73.4% (n=128; median DOR 10.7 mo); CYTOKINE RELEASE SYNDROME: Grade 3–4 CRS 4.7%; ICANS Grade 3 3.0%; cytopenia from lymphodepletion (Grade 3–4 neutropenia >90%); CAR-T MANUFACTURING FAILURES: ~8%; CILTA-CEL (ciltacabtagene autoleucel; CARTITUDE-1; BLA 125640; February 28, 2022): autologous BCMA-directed CAR-T with two BCMA-binding single-domain VHH antibody domains (biepitopic nanobody; Hamers-Casterman/Ablynx derived; 4-1BB costimulatory; lentiviral; Janssen/Legend Biotech); CARTITUDE-1 ORR 97.9% (n=97; sCR 67%); Parkinsonism/movement and neurocognitive adverse events (MNT; Grade 3 3.2%; delayed neurotoxicity distinct from ICANS); requires apheresis + manufacturing. TECLISTAMAB POSITIONING: fills the gap between ADC (no longer available in US post-withdrawal of belantamab) and CAR-T (requires manufacturing delay) as an immediate, off-the-shelf BCMA-targeted T-cell engager; the 66th mechanism class classification reflects that the BCMA×CD3 bispecific T-cell engager mechanism — simultaneous bivalent engagement of BCMA on myeloma cell AND CD3ε on T cell creating a polyclonal immunological synapse — is mechanistically distinct from all three prior BCMA effector strategies (ADC; CAR-T; future BCMA×CD28 costimulatory bispecifics like REGN5458/talquetamab CD3×GPRC5D combination).

Integrating Glyphward into Teclistamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every teclistamab CAS 2187990-05-0 monitoring data ingestion point — before Cority at Janssen Biotech Horsham PA, before VelocityEHS at Janssen Biologics BV Leiden Netherlands, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-SIXTH MECHANISM CLASS — FIRST BCMA×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761291 October 25, 2022; DuoBody IgG4 Phe405Leu + Lys409Arg Genmab technology; SC Q1W step-up then Q2W maintenance; MajesTEC-1 ORR 63.0% VGPR+ 58.5% CR 39.4% sCR 28.3%) [5 pts]; Janssen Biotech Horsham PA + Janssen Biologics BV Leiden Netherlands + Memorial Sloan Kettering New York NY [3 pts]; BCMA×CD3 bispecific absent; DuoBody Fab-arm exchange absent; SC Q2W absent; MajesTEC-1 ORR 63% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_teclistamab(cas: str, reading_ugm3: float) -> dict:
    """Scan teclistamab with sixty-sixth-class first-bcma-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_sixth_class_first_bcma_cd3_bispecific_t_cell_engager_ever_duobody_igg4_fab_arm_exchange_phe405leu_lys409arg_genmab_sc_qw_q2w_majestic1_orr_63pct_cr_39pct_janssen_bla_761291"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_sixth_class,
    #                    first_bcma_cd3_bispecific_ever, duobody_fab_arm_exchange,
    #                    phe405leu_lys409arg, sc_q2w_maintenance, majestec1_orr_63pct,
    #                    hypogammaglobulinemia_ivig, sbcma_adam10_decoy

if __name__ == "__main__":
    r = asyncio.run(scan_teclistamab("2187990-05-0", 0.00046))
    print(r)
    # {'hd_category': 1, 'sixty_sixth_class': True,
    #  'first_bcma_cd3_bispecific_ever': True,
    #  'duobody_fab_arm_exchange': True,
    #  'phe405leu_lys409arg': True,
    #  'sc_q2w_maintenance': True,
    #  'majestec1_orr_63pct': True,
    #  'sbcma_adam10_decoy': True,
    #  'hypogammaglobulinemia_ivig': True}

Related adversarial resources: Teclistamab SEO attack page (attack #639) — Blog #143: Tebentafusp SIXTY-FIFTH class (first ImmTAC; first bispecific soluble TCR; gp100/HLA-A*02:01; IMTALL OS HR 0.51) — All blogs — All SEO attacks.